FY2025 EPS Estimates for Alvotech Cut by Northland Capmk

Alvotech (NASDAQ:ALVO) – Investment analysts at Northland Capmk dropped their FY2025 earnings per share (EPS) estimates for shares of Alvotech in a research note issued to investors on Thursday, April 10th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.00 for the year, down from their prior estimate of $0.05. The consensus estimate for Alvotech’s current full-year earnings is ($0.07) per share.

Alvotech (NASDAQ:ALVO) last announced its earnings results on Wednesday, March 26th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.50. The company had revenue of $153.34 million for the quarter, compared to analysts’ expectations of $97.99 million.

Separately, UBS Group started coverage on Alvotech in a research report on Friday, February 14th. They issued a “buy” rating and a $18.00 target price on the stock.

Alvotech Stock Performance

Shares of ALVO stock opened at $8.79 on Monday. The firm has a market cap of $2.65 billion, a P/E ratio of -4.75 and a beta of -0.05. The firm’s 50 day moving average price is $10.99 and its 200-day moving average price is $11.97. Alvotech has a one year low of $7.35 and a one year high of $14.76.

Hedge Funds Weigh In On Alvotech

Several institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Alvotech during the fourth quarter worth about $74,000. Vident Advisory LLC purchased a new stake in Alvotech during the 4th quarter worth approximately $268,000. PointState Capital LP increased its stake in Alvotech by 64.1% during the 4th quarter. PointState Capital LP now owns 1,241,379 shares of the company’s stock worth $16,423,000 after buying an additional 484,826 shares during the period. ProShare Advisors LLC acquired a new stake in Alvotech during the 4th quarter worth approximately $167,000. Finally, Bank of America Corp DE boosted its position in Alvotech by 19.7% in the 4th quarter. Bank of America Corp DE now owns 16,240 shares of the company’s stock valued at $215,000 after buying an additional 2,677 shares during the period.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.